Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -1.70% is 95% above its 5-year average of -36.99%, near the high end of its 5-year range (-114.90%–0.00%).
95.19% above its 12-month average of -35.34%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-07-31): 11.27%.
RETURN ON ASSETS (ROA)
-1.70%
RETURN ON ASSETS (ROA) AVG TTM
-35.34%
RETURN ON ASSETS (ROA) AVG 3Y
-51.03%
RETURN ON ASSETS (ROA) AVG 5Y
-36.99%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+95.19%
CURRENT VS 3Y AVG
+96.67%
CURRENT VS 5Y AVG
+95.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
+94.60%
vs the sector median at left
enGene Holdings Inc.
Market Cap
$121.59M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$121.23M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$120.60M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$122.27M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$123.08M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$117.76M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$125.63M
Return on Assets (ROA)
-68.74%
TTM Avg
-454.56%
3Y Avg
-368.82%
5Y Avg
-586.69%
Market Cap
$116.80M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$116.34M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.59M | -1.70% | -35.34% | -51.03% | -36.99% |
| Seer, Inc. (SEER)vs › | $121.23M | -26.48% | -24.24% | -21.83% | -17.99% |
| Cibus, Inc. (CBUS)vs › | $120.60M | -31.33% | -56.73% | -59.49% | -64.55% |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | -96.49% | -109.25% | -126.41% | -190.40% |
| Spruce Biosciences, Inc. (SPRB)vs › | $123.08M | -49.93% | -95.40% | -72.70% | -57.07% |
| Coya Therapeutics, Inc. (COYA)vs › | $117.76M | -0.05% | -38.03% | -60.31% | -59.32% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.63M | -68.74% | -454.56% | -368.82% | -586.69% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | -53.26% | -24.98% | -43.10% | -143.56% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.34M | -72.42% | -66.03% | -45.57% | -48.77% |
| Entera Bio Ltd. (ENTX)vs › | $126.92M | -87.44% | -86.57% | -87.06% | -85.09% |
ROA
-1.7%
ROE
-2.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-10-31 | -52.97% |
| 2024-10-31 | -17.72% |
| 2023-10-31 | -114.90% |
| 2022-10-31 | -18.53% |
| 2021-10-31 | -17.83% |
| 2020-10-31 | 0.00% |
